Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

Fast Company Names egnite, Inc. One of Its Most Innovative Companies in 2024

ALISO VIEJO, Calif. – March 19, 2024 Fast Company, the world’s leading progressive business media brand, announced egnite, Inc. as one of the World’s Most Innovative Companies in their 2024 ranking. egnite, a leading digital health company specializing in artificial intelligence solutions to advance cardiovascular care, stands at the forefront of innovation in the healthcare sector.

The 2024 list showcases businesses pioneering advancements within their industries, setting new standards for innovation and paving the way for future breakthroughs. Among these trailblazers, egnite is recognized for its significant contributions to improving healthcare efficiency and patient outcomes.

In a world where heart disease remains a leading cause of mortality, with over 800,000 annual deaths in the U.S. alone, egnite’s artificial intelligence (A.I.) solutions help physicians reduce variability in care to ensure patients get the right treatment at the right time. In 2023, the company launched several new artificial intelligence technologies focused on helping physicians identify patients with risk for stroke, heart failure, and heart valve disease. Today, clinicians use egnite’s technology to screen and monitor patients, ensuring significant disease is quickly detected and treated before it’s too late.

“Gaps in care may unintentionally delay care for patients with life-threatening cardiovascular diseases. Artificial Intelligence technologies hold the potential to dramatically improve patient care and alleviate burdens on healthcare providers nationwide. Through these innovative solutions, we’re enabling providers to practice top-of-license care and ensure more patients are receiving life-saving therapy,” says Kahla Verhoef, chief product officer of egnite.  

To date, egnite’s technology:

  • Helps providers save 2 lives a day
  • Improves workflow efficiencies by up to 55%.¹
  • Increased life-saving treatment rates by 25%²

egnite’s commitment to advancing healthcare through innovative technologies underscores its position as a leader in the digital health space. As the company continues to leverage its technology to help improve patient care, it remains dedicated to shaping the future of cardiovascular health.

About egnite, Inc.

egnite is a visionary digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite uses AI-driven algorithms and big data to produce business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

References

  1. Compared to traditional screening methods
  2. Represents median growth from 17 CardioCare sites with baseline data one year after implementing the CardioCare platform.

Related Articles

egnite Research

SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?

Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.

Figure 1: Observed Mortality Stratified by GLP-1 RA and/or SGLT2i Prescription
egnite Research

Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis

BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized,

egnite Research

What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams 

On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.